International Journal of Hematology

, Volume 91, Issue 1, pp 36–45 | Cite as

Thrombotic thrombocytopenic purpura: recognition and management

Progress in Hematology Recent advance in thrombotic thrombocytopenic purpura

Abstract

Thrombotic thrombocytopenic purpura is a life-threatening multisystem disorder that represents both a diagnostic and a management challenge to clinicians. Early recognition of the condition coupled with rapid institution of plasma exchange has led to a dramatic improvement in prognosis. Studies performed over the past decade have elucidated the predominant pathophysiology, stemming from a deficiency of ADAMTS13, that accounts for the widespread microvascular deposition of platelet–von Willebrand factor in many sites, including the brain, kidney, and mesenteric vessels. However, in light of the mortality rate of 10–20%, much work remains to be done to translate advances in our understanding of pathophysiology into clinical practice. Improvements in medical management using immunosuppressive and other drugs are being actively explored in clinical trials. Agents that target ADAMTS13 autoantibody production by B-cells, such as anti-CD20 monoclonal antibodies, have the potential to shorten the duration of plasma exchange treatment, reduce relapses, and transform the management of this once enigmatic disorder.

Keywords

Thrombotic thrombocytopenic purpura (TTP) Thrombotic microangiopathy Plasma exchange ADAMTS13 

References

  1. 1.
    Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60–8.CrossRefPubMedGoogle Scholar
  2. 2.
    George JN, Terrell DR, Swisher KK, Vesely SK. Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry. J Clin Apher. 2008;23:129–37.CrossRefPubMedGoogle Scholar
  3. 3.
    Coppo P, Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Haematol Disord Drug Targ. 2009;9:36–50.CrossRefGoogle Scholar
  4. 4.
    Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haem. 2008;142:819–26.CrossRefGoogle Scholar
  5. 5.
    Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y, Wada H, et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol. 2004;41(1):68–74.CrossRefPubMedGoogle Scholar
  6. 6.
    Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt J, Lämmle B, et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor—cleaving protease activity by recombinant human ADAMTS13. Br J Haem. 2003;120:821–4.CrossRefGoogle Scholar
  7. 7.
    Scheiflinger F, Knöbl P, Trattner B, Plaimauer B, Mohr G, Dockal M, et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241–3.CrossRefPubMedGoogle Scholar
  8. 8.
    Rieger M, Mannucci PM, Hovinga JAK, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106:1262–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol. 2003;14(4):1072–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Karpac CA, Li X, Terrell DR, Kremer Hovinga JA, Lämmle B, Vesely SK, et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haem. 2008;141:696–707.CrossRefGoogle Scholar
  11. 11.
    Allford S, Hunt BJ, Rose P, Machinet SJ, On Behalf of the Haemostasis and Thrombosis Task Force of the British Committee For Standards In Hematology. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anemias. Br J Haem. 2003;120:556–73.CrossRefGoogle Scholar
  12. 12.
    Melnyk AMS, Solez K, Kjellstrand CM. Adult hemolytic-uremic syndrome. Arch Intern Med. 1995;155:2077–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005;31(6):681–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007;50:1138–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001;135:1047–51.PubMedGoogle Scholar
  16. 16.
    Park YA, Hay SN, King KE, Matevosyan K, Poisson J, Powers A, et al. Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy. J Clin Apher. 2009;24(3):115–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Uchida T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano T, et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood. 2004;104:2081–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Becker S, Fusco G, Fusco J, Balu R, Gangjee S, Brennan C, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis. 2004;39(Suppl 5):S267–75.CrossRefPubMedGoogle Scholar
  19. 19.
    Gruszecki AC, Wehrli G, Ragland BD, Reddy VVB, Nabell L, Garcia-Hernandez A, et al. Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura. Am J Hematol. 2002;69:228–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Novitsky N, Thomson J, Abraham L, du Toit C, McDonald A. TTP in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol. 2005;128:373–9.CrossRefGoogle Scholar
  21. 21.
    Francis KK, Kalyanam N, Terrell DR, Vesely SK. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist. 2007;12:11–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Oberic L, Buffet M, Schwarzinger M, Veyradier A, Clabault K, Malot S, et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist. 2009;14:769–79.CrossRefPubMedGoogle Scholar
  23. 23.
    Qu L, Kiss JE. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost. 2005;31:691–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112:11–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Mannucci PM, Peyvandi F. TTP and ADAMTS13: when is testing appropriate? Hematology. 2007;121–6.Google Scholar
  27. 27.
    Zheng XL, Kaufman RM, Goodnough LT, Sadler JE. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004;103(11):4043–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Mori Y, Wada H, Gabazza EC, Minami N, Nobori T, Shiku H, et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity. Transfusion. 2002;42:572–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Böhm M, Betz C, Miesbach W, Krause M, Auer C, Geiger H, et al. The course of ADAMTS13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haem. 2005;129:644–52.CrossRefGoogle Scholar
  30. 30.
    Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K, et al. Severe deficiency of vWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004;44:146–50.CrossRefPubMedGoogle Scholar
  31. 31.
    Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematology. 2008;93:232–9.CrossRefGoogle Scholar
  32. 32.
    Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, et al. Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood. 2007;109(7):2815–22.PubMedGoogle Scholar
  33. 33.
    Coppo P, Wolf M, Veyradier A, Bussel S, Malot GA, Millot C, et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haem. 2005;132:66–74.CrossRefGoogle Scholar
  34. 34.
    Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost. 2009;101:233–8.PubMedGoogle Scholar
  35. 35.
    Rock GA, Shuman KH, Buskard N, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–7.PubMedGoogle Scholar
  36. 36.
    Henon P. Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study. Presse Med. 1991;20:1761–7.PubMedGoogle Scholar
  37. 37.
    Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion. 2007;47:120–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Fontana S, Kremer Hovinga JA, Lämmle B, Taleghani BM. Treatment of thrombotic thrombocytopenic purpura. Vox Sang. 2006;90:245–54.CrossRefPubMedGoogle Scholar
  39. 39.
    Hay SN, Egan JA, Millward PA, Bandarenko N, Brecher ME. Patterns of platelet response in idiopathic TTP/HUS: frequency of declining platelet counts with plasma exchange and the recognition and significance of a pseudo refractory state. Ther Apher Dial. 2006;10(3):237–41.CrossRefPubMedGoogle Scholar
  40. 40.
    Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher. 1998;13:16–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Egan JA, Hay SN, Brecher ME. Frequency and significance of shistocytes in TTP/HUS patients at the discontinuation of plasma exchange therapy. J Clin Apher. 2004;19(4):165–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Bandarenko N, Members of the US TTP Apheresis Study Group. United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher. 1998;13:133–41.CrossRefPubMedGoogle Scholar
  43. 43.
    Rose M, Eldor A. High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical Study of 38 subjects. Am J Med. 1987;83:437–44.CrossRefPubMedGoogle Scholar
  44. 44.
    Onundarson PT, Rowe JM, Heal JM, Francis CW. Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. Ann Intern Med. 1992;152:791–6.CrossRefGoogle Scholar
  45. 45.
    Nguyen L, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. Transfusion. 2009;49: 392–4 (Letters To The Editor).Google Scholar
  46. 46.
    Bell WR, Braine JJ, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403.PubMedCrossRefGoogle Scholar
  47. 47.
    Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in subjects with thrombotic thrombocytopenic purpura: one institutions’ experience and review of the literature. Transfusion. 2005;45:41–9.CrossRefPubMedGoogle Scholar
  48. 48.
    George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354:1927–35.CrossRefPubMedGoogle Scholar
  49. 49.
    Ferrara F, Copia C, Annunziata M, Spasiano A, Di Grazia C, Palmieri S, et al. Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura. Ann Hematol. 1999;78:521–3.CrossRefPubMedGoogle Scholar
  50. 50.
    Crowther MA, Heddle N, Hayward CP, Warkentin T, Kelton JG. Splenectomy done during hematologic remission to prevent relapse in subjects with thrombotic thrombocytopenic purpura. Ann Intern Med. 1996;125:294–6.PubMedGoogle Scholar
  51. 51.
    Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporine and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132:146–9.Google Scholar
  52. 52.
    Cataland SR, Jin M, Zheng XL, George JN, Wu HM. An evaluation of cyclosporine alone for the treatment of early recurrences of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4:1162–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Edwards JCW, Szczepanski L, Szechinski JD, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in subjects with rheumatoid arthritis. N Engl J Med. 2004;350:2572–81.CrossRefPubMedGoogle Scholar
  55. 55.
    Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635–42.CrossRefPubMedGoogle Scholar
  56. 56.
    Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002;28:385–91.CrossRefPubMedGoogle Scholar
  57. 57.
    Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004;124:787–95.CrossRefPubMedGoogle Scholar
  58. 58.
    Millward PM, Bandarenko N, Chang PP, Stagg KF, Afenyi-Annan A, Brecher ME. Cardiogenic shock complicates successful treatment of refractory TTP with rituximab. Transfusion. 2005;45(9):1481–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003;70:183–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Foley SR, Webert K, Arnold DM, Rock GA, Clark WF, Barth D, et al. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int. 2009;75(Suppl 112):555–8.Google Scholar
  62. 62.
    George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher. 2006;21:49–56.CrossRefPubMedGoogle Scholar
  63. 63.
    Furlan M, Robles R, Galbursera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Eng J Med. 1998;339(22):1578–84.CrossRefGoogle Scholar
  64. 64.
    Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Eng J Med. 1998;339(22):1585–94.CrossRefGoogle Scholar
  65. 65.
    Veyradier A, Brivet F, Wolf M, Boyer-Neumann C, Obert B, Girma JP, et at. Total deficiency of specific von Willebrand factor-cleaving protease and recovery following plasma therapy in one patient with hemolytic-uremic syndrome. Hematol J. 2001;2(3):180–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001;98(6):1765–72.CrossRefPubMedGoogle Scholar
  67. 67.
    Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS13) and ADAMTS13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2004;12(11):891–8.Google Scholar
  68. 68.
    Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine. 2004;83(4):233–44.CrossRefPubMedGoogle Scholar
  69. 69.
    Bobbio-Pallavincini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997;82(4):429–35.Google Scholar
  70. 70.
    Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Bessa EC, et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher. 2001;16(1):19–22.CrossRefGoogle Scholar
  71. 71.
    Rock G. The management of thrombotic thrombocytopenic purpura in 2005. Sem Thromb Hemostasis. 2005;31(6):709–16.CrossRefGoogle Scholar
  72. 72.
    Mintz PD, Neff A, MacKenzie M, Goodnough LT, Hillyer C, Kessler C, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion. 2006;46(10):1659–62.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2010

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Department of MedicineUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Therapeutic Hemapheresis and Blood ServicesThe Institute for Transfusion MedicinePittsburghUSA

Personalised recommendations